Table 1 Patient’s characteristics
From: Risk factors and outcome of COVID-19 in patients with hematological malignancies
Characteristics | Hematological disease, non-SCT (n = 244) | ASCT (n = 58) | Allo-SCT (n = 65) | p value |
|---|---|---|---|---|
Age (years), median (range) | 71 (7–93) | 61 (34–75) | 48 (1–70) | < 0.0001 |
 0–40 years, n (%) | 20 (8) | 1 (2) | 25 (39) | < 0.0001 |
 41–60 years, n (%) | 51 (22) | 22 (38) | 21 (32) |  |
 61–70 years, n (%) | 45 (18) | 30 (52) | (17) (26) |  |
 >71 years, n (%) | 128 (52) | 5 (8) | 2 (3) |  |
Male, n (%) | 132 (54) | 34 (59) | 40 (61) | 0.5 |
Baseline disease, n (%) | < 0.0001 | |||
 AML | 44 (19) | 0 | 23 (35) |  |
 ALL | 12 (5) | 1 (2) | 12 (18) |  |
 MDS | 12 (5) | 0 | 10 (15) |  |
 CMPD | 27 (11) | 0 | 2 (3) |  |
 NHL | 68 (28) | 17 (30) | 6 (9) |  |
 CLL | 2 (10) | 0 | 2 (3) |  |
 Plasmatic cell disorder | 40 (16) | 38 (66) | 3 (5) |  |
 AA or auto-immune disorders | 13 (6) | 1 (2) | 5 (8) |  |
Disease status, n (%) | < 0.0001 | |||
 CR/PR | 81 (33)/45 (18) | 28 (48)/16 (28) | 56 (86)/0 |  |
 Not in remission (Rel/Ref/Prog) | 10 (4)/8 (3)/23 (9) | 5 (8)/1 (2)/6 (10) | 6 (9)/0/2 (3) |  |
 Active disease not requiring therapy | 22 (9) | 0 | 0 |  |
Prior lines of therapy | ||||
 0–1 | 189 (77) | 21 (36) | 26 (40) | < 0.001 |
 > 1 | 55 (23) | 37 (64) | 39 (60) |  |
Allo-SCT, n (%) | ||||
 HLA identical sibling |  |  | 29 (45) |  |
 Unrelated Donor |  |  | 22 (34) |  |
 Haplo-identical family donor |  |  | 14 (21) |  |
Time from transplant to COVID-19, days (range) |  | 790 (10–10661) | 441 (6–7597) | 0.1 |
Prior therapy/conditioning 40 days before COVID-19, n (%) | 102 (42) | 24 (41) | 10 (15) | < 0.0001 |
Disease diagnosed within 40 days of COVID-19, n (%) | 60 (25) | 0 | 0 | < 0.0001 |
Under immunosuppressive drugs before COVID-19 | ||||
 CNI or sirolimus or MMF | 0 | 0 | 28 (43) | < 0.0001 |
 Performance status, n (%) |  |  |  | 0.2 |
 ECOG 0–1 | 166 (68) | 48 (82) | 50 (77) |  |
 ECOG 2/ECOG 3–4 | 45 (18)/28 (11) | 7 (12)/2 (3) | 7 (11)/5 (8) |  |
Pulmonary/cardiovascular risk factors, n (%) | ||||
 Active smoking | 27 (11) | 4 (7) | 2 (3) | 0.12 |
 Arterial hypertension | 118 (48) | 12 (21) | 12 (18) | < 0.0001 |
 Cardiomyopathy | 51 (21) | 10 (17) | 4 (6) | 0.021 |
 Dyslipidemia | 78 (32) | 11 (19) | 5 (8) | < 0.0001 |
 Diabetes | 9 (4) | 3 (5) | 3 (5) |  |
Median F/U after COVID-19, days (range) | 21 (0–74) | 30 (0–72) | 35 (0–72) | 0.2 |
 Median F/U in survivors, days (range) | 33 (10–74) | 34 (11–72) | 40 (12–72) | 0.2 |